(IMUX) Immunic - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4525EP1011

Stock: Immunology Therapies, Clinical Trials, Multiple Sclerosis, Ulcerative Colitis

Total Rating 22

Risk 67

Buy Signal -0.84

Biotechnology » Biotechnology
Age: 11.8y

Market Cap: 75m
Avg Trading Vol: 816K USD

ATR: 9.02%
Peers RS (IBD): 3.00

EPS (Earnings per Share)

EPS CAGR: 17.06%
EPS Trend: 82.6%

Last SUE: 3.54
Qual. Beats: 1

Revenue

Rev. CAGR: 0.00%
Rev. Trend: 25.2%

Last SUE: 0.00
Qual. Beats: 0

Risk 5d forecast
Volatility	75.0%
Relative Tail Risk	-6.09%

Reward TTM
Sharpe Ratio	-0.23
Alpha	-52.72

Character TTM
Beta	1.002
Beta Downside	1.015

Drawdowns 3y
Max DD	82.23%
CAGR/Max DD	-0.40

Description: IMUX Immunic December 22, 2025

Imunic Inc. (NASDAQ: IMUX) is a U.S.-based biotech focused on oral small-molecule immunology drugs for chronic inflammatory and autoimmune disorders, operating primarily in the United States and Germany.

Its lead asset, IMU-838 (a DHODH inhibitor), is in Phase 3 for relapsing and progressive multiple sclerosis (MS) and in Phase 2 for moderate-to-severe ulcerative colitis. A Phase 2 candidate, IMU-856, targets intestinal-barrier restoration in celiac disease, inflammatory bowel disease, short-bowel syndrome, and IBS-D, while pre-clinical IMU-381 is aimed at broader gastrointestinal indications.

Key metrics: as of Q3 2024 the company reported a cash runway of ~ $45 million, a net-loss of $12 million YoY, and a R&D spend of $9 million, reflecting its deep-pipeline strategy. The global MS therapeutics market is projected to exceed $30 billion by 2028, and oral agents command a premium due to higher patient adherence, a sector trend that could benefit IMU-838 if Phase 3 confirms efficacy.

For a data-driven deep-dive on valuation, pipeline risk, and comparable peers, check the IMUX analysis on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income: -103.0m TTM > 0 and > 6% of Revenue
FCF/TA: -2.20 > 0.02 and ΔFCF/TA -102.5 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -2.20 > 3% & CFO -89.5m > Net Income -103.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.31 > 1.5 & < 3
Outstanding Shares: last quarter (193.9m) vs 12m ago 91.46% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.22% > 50% (prev 0.0%; Δ 0.22% > 0%)
Interest Coverage Ratio: -64.81 > 6 (EBITDA TTM -104.5m / Interest Expense TTM -1.61m)

Altman Z'' -15.00

A: 0.23 (Total Current Assets 39.3m - Total Current Liabilities 30.1m) / Total Assets 40.7m
B: -14.48 (Retained Earnings -589.3m / Total Assets 40.7m)
C: -1.98 (EBIT TTM -104.7m / Avg Total Assets 52.7m)
D: -19.42 (Book Value of Equity -586.7m / Total Liabilities 30.2m)
Altman-Z'' Score: -79.45 = D

What is the price of IMUX shares?

As of February 08, 2026, the stock is trading at USD 0.62 with a total of 1,183,557 shares traded.
Over the past week, the price has changed by -0.80%, over one month by -0.64%, over three months by -11.55% and over the past year by -36.73%.

Is IMUX a buy, sell or hold?

Immunic has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy IMUX.

StrongBuy: 5
Buy: 2
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IMUX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	5.4	767.7%
Analysts Target Price	5.4	767.7%
ValueRay Target Price	0.4	-30.6%

IMUX Fundamental Data Overview February 03, 2026

P/B = 6.9886
Revenue TTM = 114.0k USD
EBIT TTM = -104.7m USD
EBITDA TTM = -104.5m USD
Long Term Debt = 792.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 740.0k USD (from shortTermDebt, last fiscal year)
Debt = 126.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.0m USD (from netDebt column, last quarter)
Enterprise Value = 40.2m USD (75.2m + Debt 126.0k - CCE 35.1m)
Interest Coverage Ratio = -64.81 (Ebit TTM -104.7m / Interest Expense TTM -1.61m)
EV/FCF = -0.45x (Enterprise Value 40.2m / FCF TTM -89.6m)
FCF Yield = -223.1% (FCF TTM -89.6m / Enterprise Value 40.2m)
FCF Margin = -78.6k% (FCF TTM -89.6m / Revenue TTM 114.0k)
Net Margin = -90.4k% (Net Income TTM -103.0m / Revenue TTM 114.0k)
Gross Margin = -6.14% ((Revenue TTM 114.0k - Cost of Revenue TTM 121.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.99 (Enterprise Value 40.2m / Total Assets 40.7m)
Interest Expense / Debt = 1596 % (Interest Expense 2.01m / Debt 126.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -82.7m (EBIT -104.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.31 (Total Current Assets 39.3m / Total Current Liabilities 30.1m)
Debt / Equity = 0.01 (Debt 126.0k / totalStockholderEquity, last quarter 10.5m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -35.0m / EBITDA -104.5m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -35.0m / FCF TTM -89.6m)
Total Stockholder Equity = 14.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -195.4% (out of range, set to none)
RoE = -716.2% (Net Income TTM -103.0m / Total Stockholder Equity 14.4m)
RoCE = -689.5% (out of range, set to none) (EBIT -104.7m / Capital Employed (Equity 14.4m + L.T.Debt 792.0k))
RoIC = -574.7% (out of range, set to none) (NOPAT -82.7m / Invested Capital 14.4m)
WACC = 9.59% (E(75.2m)/V(75.3m) * Re(9.61%) + (debt cost/tax rate unavailable))
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 108.4%
Fair Price DCF = unknown (Cash Flow -89.6m)
EPS Correlation: 82.64 | EPS CAGR: 17.06% | SUE: 3.54 | # QB: 1
Revenue Correlation: 25.21 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.37 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+42.4% | Growth Revenue=+0.0%

Additional Sources for IMUX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle